Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVAC-1 Booster in Healthy Adults
NCT05693272Phase 1Completed
- Sponsor
- University of Saskatchewan
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of CoVac-1 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by University of Saskatchewan. Primary endpoint: Assessment of the safety of COVAC-1 booster vaccine up to 365 days. Started Jan 2023; status: completed.
02
Drugs
CoVac-1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05693272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05693272.